Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Huadong Med Acquires ADC for Ovarian Cancer in $305 Million Agreement

publication date: Oct 19, 2020

Huadong Medicine in-licensed greater China rights to an antibody-drug conjugate developed by ImmunoGen in a $305 million agreement. IMGN853 (mirvetuximab soravtansine) is in a US Phase III trial for platinum-resistant ovarian cancer, with data expected in 2021. Huadong will pay $40 million upfront and up to $265 million in milestones. Its subsidiary, Hangzhou Zhongmei Huadong Pharma, will be in charge of China development. More details....

Stock Symbols: (SHZ: 000963) (NSDQ: IMGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.